SLC27A1 and melanoma: Blocking FATP with inhibitors like Lipofermata has been shown to reduce lipid uptake in, the invasion of, and the growth of melanoma cells, demonstrating the potential of targeting adipocyte-melanoma interactions as a therapeutic strategy [116].